UBS Group
QNCX icon

UBS Group’s Quince Therapeutics QNCX Stock Holding History

UBS Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-251
Closed -$4.6M – 10609
2021
Q3 		$4.6M Buy
+251
New +$3.99M ﹤0.01% 2755

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group's QNCX Position: Q1 2026 in Review

UBS Group reduced its Quince Therapeutics (QNCX) stake by 98% in Q1 2026, selling an estimated $34.5K and leaving 3 shares worth $56. The position accounts for ﹤0.01% of the portfolio, ranked #10192.

UBS Group first reported a position in QNCX in Q2 2019 and has held it in 28 quarters since. The position peaked at $1.56M in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • UBS Group held 3 shares of Quince Therapeutics worth $56 as of Q1 2026.
  • UBS Group sold 172 Quince Therapeutics shares in Q1 2026, an estimated $34.5K.
  • Quince Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10192 holding.
  • UBS Group first reported a position in Quince Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • UBS Group's Quince Therapeutics position peaked at $1.56M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.